Navigation Links
Prescription Sleeping Pill Use Tied to Cancer

SAN DIEGO, Aug. 18 /PRNewswire/ -- The next time you consider popping a pill when you have trouble nodding off, it might be worth counting sheep instead. A senior psychiatrist at the Scripps Clinic Sleep Center in San Diego, Calif. has found evidence that taking sleeping pills regularly can increase the risk of skin cancer.

Daniel F. Kripke, M.D.'s article, based on a compilation of studies involving sleeping pills and cancer, has just been published in the Journal of Sleep Research. It appears with an editorial authored by Dr. Gary D. Friedman, an epidemiologist at Stanford University's School of Medicine and adjunct investigator at the Kaiser Permanente Medical Care Program who has vast experience in investigating the carcinogenic effects of drugs.

The effects of 556 person-years of taking either zaleplon (Sonata), Eszopiclone (Lunesta), ramelteon (Rozerem) and zolpidem (Ambien) were assessed, compared to a control group who took a placebo over 230 person-years. Kripke found eight non-melanoma skin cancers and four tumors of uncertain malignancy in the groups that took sleeping pills compared to none in the placebo groups.

Lab animals given high doses of hypnotic drugs are known to have developed kidney, thyroid and testicular cancers and suffer chromosome damage, which is a sign of carcinogenicity. Although a direct causal link between cancer and sleeping pills has still not been proven, Kripke urges additional studies as well as serious epidemiological investigations, given the fact that sleeping pill use is constantly rising and three new types have been put on the market in addition to Ambien (zolpidem), the most popular brand used in the United States.

"Because the compilation mixes diverse studies of several drugs and the number of cancers observed during controlled hypnotics trials remains small," Kripke writes, "this preliminary analysis should be viewed as an investigative step, rather than sufficient proof that modern hypnotics cause cancer."

But both he and Friedman -- who congratulated Kripke for raising this important issue even though the reviewer remained somewhat skeptical of a causal link -- urge caution and suggest that regulatory bodies and the U.S. National Institutes of Health keep an eye on cancer cases reported by sleeping pill users.

The Journal of Sleep Research is published by Wiley-Blackwell and can be accessed online at


Founded in 1924, Scripps Clinic is a multi-specialty, outpatient care facility caring for patients at multiple locations throughout San Diego County including Torrey Pines, Del Mar, Encinitas, La Jolla, Mission Valley, Rancho Bernardo, Rancho San Diego and Santee. Scripps Clinic and its physicians are world-renown for research-driven care and medical specialty expertise and is an operating unit of Scripps Health, a not-for-profit, community-based health care delivery network that includes more than 2,600 affiliated physicians, five acute-care hospitals, home health care and associated support services. Scripps Health is one of the largest health care organizations in San Diego County, drawing from the expertise of more than 10,000 health care professionals.


A researcher at Scripps Clinic has published an article in the Journal of Sleep Research indicating that people who use popular prescription sleeping pills are more likely to develop cancer than those who do not use sleeping pills.


-- Daniel Kripke, M.D., study author, Co-Director for Research, Scripps Clinic Sleep Center

SOURCE Scripps Clinic
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Lack of Medicare Part D Coverage for All Medically Necessary Prescriptions Endangers Older Americans and Those with Chronic Diseases and Disabilities
2. US FDA Grants Orphan Drug Status to Immtechs Pafuramidine for Treatment of African Sleeping Sickness
3. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
4. Immtech Receives $5.1 Million to Further African Sleeping Sickness Clinical Trials
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Novel Technology Breaks Through Cancer Pain
Post Your Comments:
(Date:11/26/2015)... DUBLIN , November 26, 2015 /PRNewswire/ ... the addition of the "Radioimmunoassay Market ... User (Hospital, Pharmaceutical Industry, Academics, Clinical Diagnostic ... - Global Forecast to 2020" report ... ) has announced the addition of the ...
(Date:11/25/2015)... DUBLIN , Nov. 25, 2015 /PRNewswire/ ... announced the addition of the "Global ... to their offering. --> ... "Global Brain Monitoring Devices Market 2015-2019" ... Research and Markets ( ) ...
(Date:11/25/2015)... OAKS, Calif. , Nov. 25, 2015  Amgen ... a Biologics License Application (BLA) with the ... (FDA) for ABP 501, a biosimilar candidate to Humira ... first adalimumab biosimilar application submitted to the FDA and ... pathway. Sean E. Harper , M.D., executive ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... ... the No.1 Herpes-only dating community in the world, revealed that over 50% of its members ... billion people under the age of 50 – or 67% of the population - are ... of HSV-1 infection . , "The data shocks us highly!" said Michelle Li, Co-Founder ...
(Date:11/27/2015)... ... 27, 2015 , ... Keeping in mind challenges faced by ... wellness consultation, has collaborated with a leading web-based marketplace for extra-curricular activities for ... parents and bring advice from parenting experts within their reach. As a part ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft ... announces the incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite ... LTS brings Q-Suite 5.10 up-to-date with a version of Asterisk that will receive ...
(Date:11/26/2015)... ... November 26, 2015 , ... The ... bioavailability and the need to integrate dose form selection in early phase drug ... the membership organization supporting and bringing together the UK’s emerging life sciences companies, ...
(Date:11/26/2015)... ... November 26, 2015 , ... Health-E-minds ... collaborated with Women’s Web – an online resource for Indian women looking ... and emotional well-being relationship, life balance, stress, professional development, and lifestyle. Health-E-minds ...
Breaking Medicine News(10 mins):